Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype

Transfusion

Volumn 55, Issue 9, 2015, Pages 2095-2103

  Kacker, Seema ^a   Vassallo, Ralph ^b   Keller, Margaret A ^b   Westhoff, Connie M ^c   Frick, Kevin D ^d   Sandler, S Gerald ^e   Tobian, Aaron A R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b American Red Cross   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIGEN; BLOOD GROUP RHESUS SYSTEM; RHO(D) ANTIGEN;

ALLOIMMUNIZATION; ARTICLE; COST CONTROL; FEMALE; GENOTYPE; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; PHENOTYPE; PREGNANT WOMAN; PROPHYLAXIS; SENSITIVITY ANALYSIS; SEROLOGIC WEAK D PHENOTYPE; SEROLOGY; UNITED STATES; ADULT; BLOOD GROUP RHESUS SYSTEM; COST; ECONOMICS; ERYTHROBLASTOSIS, FETAL; GENETICS; GENOTYPING TECHNIQUE; PREGNANCY; PROBABILITY; PROCEDURES; STATISTICAL MODEL;

ADULT; COSTS AND COST ANALYSIS; ERYTHROBLASTOSIS, FETAL; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM; UNITED STATES;

EID: 84941800042     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13074     Document Type: Article

References (27)

1. Crowther CA, Middleton P, McBain RD,. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2013; 2: CD000020.
2. Moise KJ Jr., Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008; 112: 164-76.
3. Bowman J,. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43: 1661-6.
4. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 75: Management of alloimmunization during pregnancy. Obstet Gynecol 2006; 108: 457-64.
5. Wagner FF, Gassner C, Müller TH, et al., Molecular basis of weak D phenotypes. Blood 1999; 93: 38 5- 93.
6. Jenkins CM, Johnson ST, Bellissimo DB, et al., Incidence of weak D in blood donors typed as D positive by the Olympus PK 7200. Immunohematology 2005; 21: 152-4.
7. Chou ST, Jackson T, Vege S, et al., High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122: 1062-71.
8. Cruz BR, Chiba AK, Moritz E, et al., RHD alleles in Brazilian blood donors with weak D or D-negative phenotypes. Transfus Med 2012; 22: 84-9.
9. Friedlaender JS, Friedlaender FR, Reed FA, et al., The genetic structure of Pacific Islanders. PLoS Genet 2008; 4: e19.
10. Roseff SD., Standards for blood banks and transfusion services. 29th ed. Bethesda (MD): AABB; 2014.
11. Sandler SG, Roseff SD, Domen RE, et al., Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the comprehensive transfusion medicine survey of the College of American Pathologists. Arch Pathol Lab Med 2014; 138: 620-5.
12. Sandler SG, Flegel WA, Westhoff CM, et al., It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion 2015; 55: 680-9.
13. Briggs A, Sculpher M,. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.
14. US Census Bureau. Table PEPASR6H: annual estimates of the resident population by sex, age, race, and Hispanic origin for the United States and States: April 1, 2010 to July 1, 2013. Washington (DC): US Census Bureau, Population Division; 2014 Jun [cited 2014 Jul 17]. Available from: http://factfinder2.census.gov
15. Centers for Disease Control and Prevention. Underlying cause of death 1999-2013 on CDC WONDER online database. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Health Statistics. Released 2014 [cited 2014 Jul 17]. Available from: http://wonder.cdc.gov/ucd-icd10.html
16. Hamilton BE, Martin JA, Osterman MJ, et al., Births: preliminary data for 2013. Volume 63, No. 2. Hyattsville (MD): US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System; 2014 May 29 [cited 2014 Jul 17]. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr63/nvsr63-02.pdf
17. MacDorman MF, Mathews TJ, Declercq E., Trends in out-of-hospital births in the United States, 1990-2012. NCHS Data Brief, Number 144, March, 2014. Hyattsville (MD): National Center for Health Statistics; 2014 [cited 2014 Aug 7]. Available from: http://www.cdc.gov/nchs/data/databriefs/db144.pdf%3E
18. US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau. Child health USA 2013: prenatal care utilization. Rockville (MD): US. Department of Health and Human Services; 2013 [cited 2014 Aug 15]. Available from: http://mchb.hrsa.gov/chusa13/health-services-utilization/p/prenatal-care-utilization.html%3E
19. Garratty G, Glynn SA, McEntire R,. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 2004; 44: 703-6.
20. Yan L, Wu J, Zhu F, et al., Molecular basis of D variants in Chinese persons. Transfusion 2007; 47: 471-7.
21. Wu JJ, Hong XZ, Xu XG, et al., Molecular basis of partial D phenotypes in Chinese. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006; 14: 587-91.
22. Ye SH, Wu DZ, Wang MN, et al., A comprehensive investigation of RHD polymorphisms in the Chinese Han population in Xi'an. Blood Transfus 2014; 12: 396-404.
23. Reid ME, Halter Hipsky C, Hue-Roye K, et al., Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease. Blood Cells Mol Dis 2014; 52: 195-202.
24. Reid ME, Lomas-Francis C., Blood group antigens and antibodies: a guide to clinical relevance and technical tips. 2nd ed. New York: SBB Books; 2007.
25. Hawk AF, Chang EY, Shields SM, et al., Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol 2013; 122: 579-85.
26. American Association of Blood Banks. Medicare 2014 hospital outpatient PPS final rule-summary of major provisions affecting transfusion medicine and cellular therapies. Bethesda (MD): AABB; 2014 [cited 2014 Aug 16]. Available from: http://www.aabb.org/advocacy/reimbursementinitiatives/Pages/14hoppsrulefinal.aspx
27. Centers for Medicare & Medicaid Services. Hospital outpatient prospective payment system: addendum A update. Centers for Medicare & Medicaid Services; 2012 [cited 2014 Aug 15]. Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates-Items/2012-July-Addendum-A.html?DLPage=3&DLSort=2&DLSortDir=descending